Divi's Laboratories Limited

Healthcare IN DIVISLAB

6651.0INR
74.50(1.13%)

Last update at 2026-06-04T06:46:00Z

Day Range

6521.006700.00

LowHigh

52 Week Range

4932.547039.45

LowHigh

Fundamentals

Previous Close 6576.50
Market Cap1752225.28M
Volume133605
P/E Ratio70.47
Dividend Yield-%
EBITDA32460.00M
Revenue TTM100290.00M
Revenue Per Share TTM377.74
Gross Profit TTM 60970.00M
Diluted EPS TTM93.66

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Income before tax	29160.00M	21630.00M	23686.30M	36835.00M	26660.40M
Minority interest	0.00000M	0.00000M	0.00000M	0.00000M	0.00000M
Net income	21910.00M	16000.00M	18240.00M	29604.50M	19842.90M
Selling general administrative	1430.00M	1250.00M	1260.00M	1085.90M	831.40M
Selling and marketing expenses	1360.00M	900.00M	1140.00M	1270.10M	1240.30M
Gross profit	31910.00M	45270.00M	44870.00M	57073.50M	45342.60M
Reconciled depreciation	4020.00M	3780.00M	3431.80M	3115.10M	2555.90M
Ebit	29190.00M	21650.00M	23705.90M	36854.90M	26681.30M
Ebitda	33210.00M	25430.00M	27137.70M	39970.00M	29237.20M
Depreciation and amortization	4020.00M	3780.00M	3431.80M	3115.10M	2555.90M
Non operating income net other	-	-	-	-	-
Operating income	26380.00M	19520.00M	20622.10M	35737.70M	26159.90M
Other operating expenses	67200.00M	59640.00M	56866.00M	52254.60M	42423.50M
Interest expense	30.00M	30.00M	19.60M	19.90M	20.90M
Tax provision	7250.00M	5630.00M	5452.50M	7230.50M	6817.50M
Interest income	3480.00M	3010.00M	3389.70M	8.00M	52.50M
Net interest income	-20.00000M	-30.00000M	-6.70000M	-8.00000M	-8.70000M
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	7250.00M	5630.00M	5452.50M	7230.50M	6817.50M
Total revenue	93580.00M	77960.00M	77488.10M	87992.30M	68583.40M
Total operating expenses	5530.00M	4610.00M	4914.10M	21335.80M	19182.70M
Cost of revenue	61670.00M	32690.00M	51951.90M	30918.80M	23240.80M
Total other income expense net	2780.00M	2110.00M	3064.20M	1097.30M	500.50M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	21910.00M	16000.00M	18233.80M	29604.50M	19842.90M
Net income applicable to common shares	21910.00M	16000.00M	18233.80M	29604.50M	19842.90M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Total assets	169470.00M	154700.00M	144387.70M	133747.10M	107740.70M
Intangible assets	40.00M	40.00M	52.80M	74.90M	49.50M
Earning assets	-	-	-	-	-
Other current assets	650.00M	6320.00M	2017.70M	2175.50M	1531.90M
Total liab	19780.00M	18990.00M	16716.80M	16465.30M	14794.60M
Total stockholder equity	149690.00M	135710.00M	127670.90M	117281.80M	92946.10M
Deferred long term liab	-	-	-	-	-
Other current liab	5000.00M	8950.00M	2875.60M	3990.30M	-47.20000M
Common stock	530.00M	530.00M	530.90M	530.90M	530.90M
Capital stock	530.00M	530.00M	530.90M	530.90M	530.90M
Retained earnings	134000.00M	117860.00M	109581.10M	99888.50M	75977.20M
Other liab	-	-	-	4481.10M	3633.10M
Good will	-	-	-	-	-
Other assets	750.00M	680.00M	956.70M	1562.20M	1848.60M
Cash	4320.00M	3630.00M	1697.00M	12147.60M	20303.20M
Cash and equivalents	3940.00M	3400.00M	1407.70M	11928.80M	20085.20M
Total current liabilities	14520.00M	12780.00M	11010.80M	11955.50M	11124.60M
Current deferred revenue	400.00M	340.00M	505.20M	-	3528.40M
Net debt	-4280.00000M	-3600.00000M	-1664.40000M	-12110.70000M	-20254.90000M
Short term debt	20.00M	20.00M	4.90M	8.20M	11.40M
Short long term debt	20.00M	0.00000M	0.00000M	0.00000M	3.50M
Short long term debt total	40.00M	30.00M	32.60M	36.90M	48.30M
Other stockholder equity	800.00M	17060.00M	17558.90M	16862.40M	16438.00M
Property plant equipment	64600.00M	55130.00M	49292.00M	47874.90M	44095.40M
Total current assets	100810.00M	96750.00M	93117.40M	83515.00M	61747.10M
Long term investments	-	-	-	-	-
Net tangible assets	-	-	-	117206.90M	92896.60M
Short term investments	31240.00M	33380.00M	40494.60M	15270.10M	546.40M
Net receivables	29780.00M	21580.00M	18904.00M	25635.60M	17913.30M
Long term debt	-	-	-	-	-
Inventory	33230.00M	31840.00M	30004.10M	28286.20M	21452.30M
Accounts payable	9100.00M	8240.00M	7625.10M	7957.00M	7632.00M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	14360.00M	260.00M	-	-	-
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	640.00M	1660.00M	40996.30M	16930.10M	2348.20M
Deferred long term asset charges	-	-	-	-	-
Non current assets total	68660.00M	57950.00M	51270.30M	50232.10M	45993.60M
Capital lease obligations	20.00M	30.00M	32.60M	36.90M	44.80M
Long term debt total	20.00M	20.00M	27.70M	28.70M	36.90M

Breakdown	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Investments	-8040.00000M	-2690.00000M	-27076.20000M	-15485.30000M	9281.60M
Change to liabilities	-	-	0.00000M	342.70M	1748.00M
Total cashflows from investing activities	-10990.00000M	-2690.00000M	-27076.20000M	-21949.20000M	751.30M
Net borrowings	-	-	-	-11.40000M	-340.20000M
Total cash from financing activities	-7970.00000M	-7990.00000M	-7971.70000M	-5324.40000M	-348.90000M
Change to operating activities	-	-	-	202.90M	1078.90M
Net income	21910.00M	16000.00M	23686.30M	36835.00M	26660.40M
Change in cash	610.00M	1930.00M	-10450.60000M	-8155.60000M	19871.70M
Begin period cash flow	3710.00M	1700.00M	12147.60M	20303.20M	431.50M
End period cash flow	4320.00M	3630.00M	1697.00M	12147.60M	20303.20M
Total cash from operating activities	19460.00M	12610.00M	24597.30M	19118.00M	19469.30M
Issuance of capital stock	-	-	-	-	-
Depreciation	4020.00M	3780.00M	3431.80M	3115.10M	2555.90M
Other cashflows from investing activities	35410.00M	3000.00M	-22346.00000M	668.10M	570.10M
Dividends paid	-7960.00000M	-7960.00000M	7964.10M	5309.40M	5309.40M
Change to inventory	-520.00000M	-1840.00000M	-1717.90000M	-6833.90000M	-2813.70000M
Change to account receivables	-5820.00000M	-3610.00000M	6504.10M	-7416.20000M	-2653.10000M
Sale purchase of stock	-	-	-	-	-
Other cashflows from financing activities	-10.00000M	-20.00000M	-7.60000M	-15.00000M	-16.10000M
Change to netincome	-	-	-	102.90M	-288.70000M
Capital expenditures	14380.00M	10030.00M	4730.20M	7132.00M	9101.90M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	-5540.00000M	-6070.00000M	4188.10M	-13704.50000M	-2640.80000M
Stock based compensation	-	-	-	-	-
Other non cash items	-930.00000M	-1100.00000M	-6708.90000M	-7127.60000M	-7106.20000M
Free cash flow	5080.00M	2580.00M	19867.10M	11986.00M	10367.40M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company	Change (INR)	Price (INR)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
DIVISLAB Divi's Laboratories Limited	74.50 1.13%	6651.00	70.47	-	17.47	11.44	17.33	47.08
SUNPHARMA Sun Pharmaceutical Industries Limited	-9.4 0.53%	1779.10	40.32	26.95	7.69	5.50	7.41	23.64
TORNTPHARM Torrent Pharmaceuticals Limited	-3.6001 0.08%	4364.90	63.48	56.50	11.13	16.39	11.65	35.91
CIPLA Cipla Limited	14.50 1.05%	1389.70	21.74	19.01	4.23	3.76	4.08	14.00
DRREDDY Dr. Reddy's Laboratories Limited	2.60 0.21%	1265.90	17.16	21.93	2.94	2.89	2.99	10.39

Reports Covered

View All

Profile

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Divi's Laboratories Limited

Divi Towers, Hyderabad, India, 500032

91 40 6696 6300
https://www.divislabs.com
Employees : 10542

Key Executives

Name	Title	Year Born
Dr. Kiran Satchandra Divi B. Pharm., M.Pharm	CEO & Whole-Time Director	1976
Mr. L. Kishore Babu B.Com, FCMA, FICWA	Chief Financial Officer	1952
Mr. L. Ramesh Babu LLB, M.Com, MBA	VP of Procurement & Chief Information Officer	1957
Mr. M. Satish Choudhury	Company Sec. & Compliance Officer	NA
Mr. Venkata Ramana Nimmagadda B.Sc.(Chem)	Exec. Director	1958
Dr. Murali Krishna Prasad Divi M. Pharm, Ph.D.	MD & Exec. Director	1951
Mr. Madhusudana Rao Divi	Director of Projects & Whole-Time Director	1944
Mr. M. Ramesh Babu B.Sc.	Chief Technologist	1966
Mr. P. Srinivasa Rao M.Pharm	Chief Technologist	1965
Ms. Nilima Prasad Divi	Whole-time Director & Director of Commercial	1982

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.